Voyager Therapeutics, Inc. (VYGR) financial statements (2021 and earlier)

Company profile

Business Address 75 SIDNEY STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments181282156169174194
Cash and cash equivalents1048647323731
Short-term investments77195109138138163
Prepaid expense101110
Contract with customer, asset818 
Other current assets221 00
Other undisclosed current assets625231
Total current assets:198305162172179196
Noncurrent Assets
Operating lease, right-of-use asset3628
Property, plant and equipment2518131083
Long-term investments and receivables 211130
Long-term investments 211130
Other undisclosed noncurrent assets221120
Total noncurrent assets:645015131134
TOTAL ASSETS:262355177184190229
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1526111374
Accounts payable141111
Accrued liabilities1422101163
Deferred revenue847
Deferred revenue and credits3720
Contract with customer, liability21
Other liabilities43    
Total current liabilities:277632161424
Noncurrent Liabilities
Liabilities, other than long-term debt8017999354036
Deferred revenue and credits344036
Deferred revenue36147
Contract with customer, liability92
Deferred rent credit  6
Other liabilities44321100
Total noncurrent liabilities:8017999354036
Total liabilities:107255131505460
Stockholders' equity
Stockholders' equity attributable to parent15410046134136169
Common stock000000
Additional paid in capital430412316295226219
Accumulated other comprehensive loss(0)(0)(0)(0)(0)(0)
Accumulated deficit(276)(313)(269)(161)(90)(50)
Total stockholders' equity:15410046134136169
TOTAL LIABILITIES AND EQUITY:262355177184190229

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues1711048101417
Cost of revenue
(Financial Services Costs)
     (10)
Gross profit:171104810148
Operating expenses(144)(156)(99)(82)(56)(38)
Other undisclosed operating income     10
Operating income (loss):27(52)(91)(72)(41)(20)
Nonoperating income98311 
Other nonoperating income (expense)82(1)(0)0 
Interest and debt expense     (9)
Income (loss) from continuing operations before income taxes:37(44)(88)(71)(40)(30)
Income tax expense (benefit)  0 (0) 
Net income (loss) attributable to parent:37(44)(88)(71)(40)(30)
Preferred stock dividends and other adjustments     (9)
Net income (loss) available to common stockholders, diluted:37(44)(88)(71)(40)(38)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):37(44)(88)(71)(40)(30)
Comprehensive income (loss):37(44)(88)(71)(40)(30)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00(0)0(0)
Comprehensive income (loss), net of tax, attributable to parent:37(44)(88)(71)(40)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: